表紙
市場調查報告書

醣生物學的全球市場:各產品類型、應用、終端用戶、地理的成長率,趨勢及預測(2018年∼2023年)

Glycobiology Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 661003
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
Back to Top
醣生物學的全球市場:各產品類型、應用、終端用戶、地理的成長率,趨勢及預測(2018年∼2023年) Glycobiology Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

醣生物學,預計從2018年到2023年的預測期間內,以約13%的年複合成長率成長。醣生物學,是生命科學重要的領域,包含在細菌生理學的研究,新藥物的開發及蛋白質體學研究中發揮多樣作用的糖鎖鏈的研究。研究人員為了糖鎖鏈應用,活用質譜分析,MALDI-TOF等各種技術。因此,含質譜儀及MALDI-TOF質譜儀的醣生物學設備的需求,預計不久的將來將增加。

本報告提供全球醣生物學市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 政府及民間對醣生物學及蛋白質體學研究的資金籌措增加
    • 醫藥品及生物科技企業的研究開發費的增加
  • 市場阻礙因素
    • 高的產品成本
    • 熟練專家的低可用性
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品
    • 酵素
    • 器具
    • 套件
    • 試劑
  • 各應用領域
    • 診斷
    • 藥物研發開發
    • 腫瘤學
    • 免疫學
    • 其他
  • 終端用戶
    • 醫藥品及生物科技企業
    • 契約研究機關(CRO)
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Agilent Technologies
  • Bruker Corporation
  • Danaher Corporation
  • Merck KGaA
  • New England Biolabs
  • ProZyme
  • 島津製作所
  • TaKaRa BIO
  • Thermo Fisher Scientific
  • Waters Corporation 等

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53251

The glycobiology market will show rapid growth due to the increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies.

  • The major pharmaceutical and biotech companies are heavily investing in the research and development of superior biological products, such as glycobiology products and products related to proteomics.
  • There is also an increased demand for curative treatments for many life-threatening diseases, such as cancer, which is expected to drive the pace of pharmaceutical and biotechnological R&D, as well as overall investments made in glycobiology field. This makes glycobiology an attractive option for big pharma and biotech companies to invest in. Furthermore, glycomic biomarkers have significant applications in drug development and diagnostics for many diseases.
  • In addition, a huge amount of investment is put into the development of its products and the approval of drugs that are developed, require a lot of regulatory stages that are necessary for the process. This, in turn, renders these products very expensive.

Key Market Trends

Drug Discovery and Development is Expected to be the Largest Growing Segment

On the basis of application, drug discovery and development has been accounted for the largest market share. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. There is an increasing R&D investments by pharmaceutical companies, which increases the drug discovery and development of glycomics. For instance, R&D expenditure of Merck accounted for USD 9.8 billion, in 2018.

The other applications segment is anticipated to witness the high CAGR due to rising clinical trials and R&D expenses incurred by key companies for research.

North America is Found Leading the Glycobiology Market

North America has been accounted for the largest market share due to the presence of key pharmaceutical and biopharmaceutical companies. The presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, there is also increasing applications of glycans in various cancers and increasing funds from the government in enhancing the field of glycobioogy, that helps the market to grow over the forecast period.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies undertaken by these companies for sustainable growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
    • 4.2.2 Growing R&D Expenditure by Pharmaceutical and

Biotechnology Companies

  • 4.3 Market Restraints
    • 4.3.1 High Product Cost
    • 4.3.2 Low Availability of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Enzymes
    • 5.1.2 Instruments
    • 5.1.3 Kits
    • 5.1.4 Reagents
  • 5.2 By Application
    • 5.2.1 Diagnostics
    • 5.2.2 Drug Discovery and Development
    • 5.2.3 Oncology
    • 5.2.4 Immunology
    • 5.2.5 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Research Organizations
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Bruker Corporation
    • 6.1.3 Danaher Corporation
    • 6.1.4 Merck KGaA
    • 6.1.5 New England Biolabs
    • 6.1.6 ProZyme
    • 6.1.7 Shimadzu Corporation
    • 6.1.8 Takara Bio
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top